UK MHRA approves Vertex’s Alyftrek, a once-daily next-in-class CFTR modulator to treat cystic fibrosis
Vertex Pharmaceuticals, a global biotechnology company, announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Alyftrek (deutivacaftor/tezacaftor/vanzacaftor), a once-daily next-in …